Full Data For Seattle Genetics’ Lymphoma Drug Shine Bright Light On Antibody Drug Conjugates
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Seattle Genetics and partner Takeda are revising their regulatory strategy and will file their antibody drug conjugate SGN-35 in the first quarter of 2011 for both Hodgkin's lymphoma and anaplastic large cell lymphoma, following a positive reception for their pivotal data at the American Society of Hematology annual meeting.
You may also be interested in...
Takeda Caught Surprised By Outcomes For Two Key Products
TOKYO - Takeda Pharmaceuticals' highly positive Phase III data for antibody drug conjugate SGN-35 (brentuximab vedotin) - partnered with Seattle Genetics - is a bright spot for the company after a "complete response" letter to partner Orexigen for obesity drug Contrave (bupropion/naltrexone)
Seattle Genetics Looks Ahead To BLA Filing For Its Antibody Drug Conjugate
Better-than-expected response rates in pivotal Hodgkin lymphoma trial have company and the Street hopeful for an easy regulatory review.
Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials
Days after losing Roche/Genentech as a partner for dacetuzumab, Seattle Genetics signs Takeda as a partner for a late-stage antibody-drug conjugate.